Table 4.
Features of the Oncotype-DX DCIS and DCISionRT commercial tests
| Oncotype-DX DCIS [72] | DCISionRT [73] | |
|---|---|---|
| Cost | ~ $3000 USD | ~ $1500 USD |
| Type of molecular signature | Gene expression via RT-PCR | Biomarker expression via IHC coupled with clinical features |
| Genes/markers/clinical features | Ki-67, STK15, Survivin, CCNB1, MYBL2, PR, GSTM1 (cancer related genes) & ACTB, GAPDH, RPLPO, GUS, TFRC (housekeeping genes) | COX2, FOXA1, HER2, Ki-67, p16/CDKN2A, PR, SIAH2 (IHC) and patient age, tumor size, margin status and palpability |
| Range of score | 0–100 | 0–10 |
| Scoring risk of local recurrence |
Low risk score < 39 Intermediate risk score = 39–54 High risk score 55 |
low risk score < 3 high risk score > 3 |